-
2023-508730-34-00
9
2024-07-10
Non-small cell lung cancer (NSCLC):
- Locally advanced NSCLC where par
-
2022-502049-91-00
4
2023-09-26
SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
-
2024-515994-83-00
5
2026-01-13
aneurysmal subarachnoid hemorrhage with a vasospasm
-
2024-515391-12-00
1
2025-03-15
Advanced Solid Tumors with AKT1 E17K Mutation
-
2023-503218-56-00
4
2025-01-30
Adult patients with a histologically confirmed TLS-positive advanced o
-
2024-519977-20-00
4
2025-01-27
Acute Anterior Ischemic Optic Neuropathy associated with Giant Cell Ar
-
2024-512278-92-00
4
2024-12-09
Pulmonary Arterial Hypertension (PAH)
-
2024-516717-20-00
3
2024-11-27
Metastatic non small cell lung cancer (Phase I and expansion cohorts)
-
2023-508812-45-00
10
2024-11-11
Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
-
2024-513648-27-00
4
2024-10-25
Patients with newly or active diffuse Systemic sclerosis (SSc) at the
-
2024-517400-11-00
6
2024-10-24
Patients with metastatic breast cancer initially presenting with overe
-
2024-511363-28-00
5
2024-09-24
hidradenitis suppurativa (HS)
-
2024-516299-13-00
4
2024-09-06
Resectable Gastric Cancer
-
2024-516005-23-00
4
2024-08-22
metastatic squamous cell anal carcinoma
-
2023-508356-19-00
4
2024-06-25
Pancreatic adenocarcinoma metastatic
-
2023-506823-28-00
4
2024-06-14
Adult patients with locally advanced/metastatic solid tumors
-
2023-505712-37-00
10
2024-06-06
The participants must have a histologically confirmed diagnosis of res
-
2022-502653-34-01
11
2024-05-30
Atopic dermatitis and moderate-to severe atopic hand eczema
-
2023-503223-26-00
9
2024-05-07
Advanced Solid Tumors Harboring a KRASG12C Mutation
-
2023-507125-41-00
9
2024-03-25
Advanced or Metastatic Breast Cancer
-
2022-502461-23-00
5
2024-02-15
Prurigo Nodularis
-
2023-503739-16-00
1
2023-12-20
Relapsed or refractory solid tumors or non-Hodgkin lymphoma
-
2023-505108-52-00
5
2023-12-20
Intensive Care
-
2022-503160-33-00
5
2023-12-15
Hidradenitis Suppurativa